Marta Palafox

TL;DR: It is reported that ER-positive breast cancer cells can adapt quickly to CDK4/6 inhibition and evade cytostasis, in part, via noncanonical cyclin D1-CDK2-mediated S-phase entry, highlighting strategies to prevent the acquisition of therapeutic resistance to these agents.

TL;DR: The findings suggest that RANK expression in primary breast cancer associates with poor prognosis, and RANK promotes tumor initiation, progression, and metastasis in human mammary epithelial cells by increasing the population of CD44(+)CD24(-) cells, inducing stemness and EMT.

TL;DR: The results indicate that MSK1 prevents metastatic progression of ER+ breast cancer, suggesting that stratifying patients with breast cancer as high or low risk for early relapse based on MSK 1 expression could improve prognosis.

TL;DR: A transcriptional signature of resistance, predictive of recurrent disease after chemotherapy in TNBC, is described and a drug holiday effect on the acquired resistance to docetaxel in triple-negative breast cancer is evidence.

TL;DR: It is shown that the simultaneous blockade of FASN and HER2 pathways is effective in cells and in breast cancer models refractory to anti-HER2 therapies.